Key Findings
- PD-L1 expression in GIST is associated with adverse outcomes, including significantly worse progression-free survival and more advanced disease features.
- Nearly 21% of treatment-naïve GISTs showed PD-L1 expression, identifying a biologically distinct subset within the clinical spectrum of GIST.
- Despite harboring immunotherapy-sensitive driver mutations, PD-L1-positive tumors had worse outcomes, highlighting PD‑L1 as a potential prognostic biomarker and therapeutic target in select GIST subsets.